Direction of new drug R&D in Chinese materia medica over therapeutic field of new drugs approved by CFDA during 2010-2014
10.7501/j.issn.0253-2670.2015.15.026
- Author:
Jing-Bo ZHANG
1
Author Information
1. Shenyang Pharmaceutical University
- Publication Type:Journal Article
- Keywords:
Cardiovascular system;
Direction of research and development;
New drug of Chinese materia medica;
Therapeutic field;
Urogenital system
- From:
Chinese Traditional and Herbal Drugs
2015;46(15):2339-2342
- CountryChina
- Language:Chinese
-
Abstract:
To provide the reference for selecting the research and development trend and direction of new drug in Chinese materia medica (CMM). We sorted out the new drugs of CMM approved by the China Food and Drug Administration (CFDA) during 2010-2014 through database retrieval, analyzed their indications, declared period and approval rates, then discuss and suggest the predominance of CMM for research and development. In recent five years, among the new drugs of CMM approved by CFDA, their main indications are those for cardiovascular system, respiratory system, and urogenital system. The declared period from short to long is gynaecology system, respiratory system, and urogenital system. From the point of approval rates, urogential system and pediatric system are higher than others. Comprehensive the above three factors, we get that cardiovascular system is a classic indication for CMM; Urogenital system, pediatrics system and gynecologic system will be the potential fields for CMM research and development.
